A two-step timed sequential treatment for acute myelocytic leukemia

R. B. Geller, P. J. Burke, Judith Karp, Richard L Humphrey, H. G. Braine, R. W. Tucker, M. G. Fox, M. Zahurak, L. Morrell, K. L. Hall, S. Piantadosi

Research output: Contribution to journalArticle

Abstract

Since 1980, adults with acurate myelocytic leukemia (AML) have been treated on two clinical studies using intensive timed sequential therapy. All patients ages 16 to 80, including those with secondary AML (SAML) and those with AML preceded by a hematologic disorder (AHD), were treated, regardless of medical complications at the time of diagnosis. The first study combined high doses of cytarabine (ara-C, AC) and daunorubicin (DRN, D) in sequence (Ac2-D-Ac) and resulted in a complete remission rate of 55%. A group of these patients selected by functional status was able to receive a second course of therapy in remission, which resulted in a disease-free survival (DFS) of >40% at 7 years. Because of toxicity in that study, 114 patients were entered on a second trial initiated 4 years ago, using a less aggressive first course, with amsacrine, to achieve a stable remission (Ac2-D-Amsa). The first treatment was followed by a more intensive second course (Ac6-D-Ac). With this two-step approach, a higher complete remission (CR) rate (76% for the de novo AML and 54% for SAML-AHD) was achieved, and more patients were able to receive the second course of therapy. At the current median follow-up of 26 months, the median duration of DFS and overall survival are 11 and 14 months for patients with de novo AML. Age ≤55 is the most significant prognostic factor for both prolonged DFS and overall survival, with median durations of 17 and 18 months, respectively, for these younger patients. Patients with SAML-AHD remain relatively refractory to treatment despite aggressive chemotherapy, with median durations of DFS and overall survival of 9 months and 5 months, respectively.

Original languageEnglish (US)
Pages (from-to)1499-1506
Number of pages8
JournalBlood
Volume74
Issue number5
StatePublished - 1989

Fingerprint

Acute Myeloid Leukemia
Myeloid Leukemia
Cytarabine
Disease-Free Survival
Amsacrine
Daunorubicin
Chemotherapy
Therapeutics
Survival
Refractory materials
Toxicity
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Geller, R. B., Burke, P. J., Karp, J., Humphrey, R. L., Braine, H. G., Tucker, R. W., ... Piantadosi, S. (1989). A two-step timed sequential treatment for acute myelocytic leukemia. Blood, 74(5), 1499-1506.

A two-step timed sequential treatment for acute myelocytic leukemia. / Geller, R. B.; Burke, P. J.; Karp, Judith; Humphrey, Richard L; Braine, H. G.; Tucker, R. W.; Fox, M. G.; Zahurak, M.; Morrell, L.; Hall, K. L.; Piantadosi, S.

In: Blood, Vol. 74, No. 5, 1989, p. 1499-1506.

Research output: Contribution to journalArticle

Geller, RB, Burke, PJ, Karp, J, Humphrey, RL, Braine, HG, Tucker, RW, Fox, MG, Zahurak, M, Morrell, L, Hall, KL & Piantadosi, S 1989, 'A two-step timed sequential treatment for acute myelocytic leukemia', Blood, vol. 74, no. 5, pp. 1499-1506.
Geller RB, Burke PJ, Karp J, Humphrey RL, Braine HG, Tucker RW et al. A two-step timed sequential treatment for acute myelocytic leukemia. Blood. 1989;74(5):1499-1506.
Geller, R. B. ; Burke, P. J. ; Karp, Judith ; Humphrey, Richard L ; Braine, H. G. ; Tucker, R. W. ; Fox, M. G. ; Zahurak, M. ; Morrell, L. ; Hall, K. L. ; Piantadosi, S. / A two-step timed sequential treatment for acute myelocytic leukemia. In: Blood. 1989 ; Vol. 74, No. 5. pp. 1499-1506.
@article{1024ecd204e54130b254781c8ad8f47b,
title = "A two-step timed sequential treatment for acute myelocytic leukemia",
abstract = "Since 1980, adults with acurate myelocytic leukemia (AML) have been treated on two clinical studies using intensive timed sequential therapy. All patients ages 16 to 80, including those with secondary AML (SAML) and those with AML preceded by a hematologic disorder (AHD), were treated, regardless of medical complications at the time of diagnosis. The first study combined high doses of cytarabine (ara-C, AC) and daunorubicin (DRN, D) in sequence (Ac2-D-Ac) and resulted in a complete remission rate of 55{\%}. A group of these patients selected by functional status was able to receive a second course of therapy in remission, which resulted in a disease-free survival (DFS) of >40{\%} at 7 years. Because of toxicity in that study, 114 patients were entered on a second trial initiated 4 years ago, using a less aggressive first course, with amsacrine, to achieve a stable remission (Ac2-D-Amsa). The first treatment was followed by a more intensive second course (Ac6-D-Ac). With this two-step approach, a higher complete remission (CR) rate (76{\%} for the de novo AML and 54{\%} for SAML-AHD) was achieved, and more patients were able to receive the second course of therapy. At the current median follow-up of 26 months, the median duration of DFS and overall survival are 11 and 14 months for patients with de novo AML. Age ≤55 is the most significant prognostic factor for both prolonged DFS and overall survival, with median durations of 17 and 18 months, respectively, for these younger patients. Patients with SAML-AHD remain relatively refractory to treatment despite aggressive chemotherapy, with median durations of DFS and overall survival of 9 months and 5 months, respectively.",
author = "Geller, {R. B.} and Burke, {P. J.} and Judith Karp and Humphrey, {Richard L} and Braine, {H. G.} and Tucker, {R. W.} and Fox, {M. G.} and M. Zahurak and L. Morrell and Hall, {K. L.} and S. Piantadosi",
year = "1989",
language = "English (US)",
volume = "74",
pages = "1499--1506",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - A two-step timed sequential treatment for acute myelocytic leukemia

AU - Geller, R. B.

AU - Burke, P. J.

AU - Karp, Judith

AU - Humphrey, Richard L

AU - Braine, H. G.

AU - Tucker, R. W.

AU - Fox, M. G.

AU - Zahurak, M.

AU - Morrell, L.

AU - Hall, K. L.

AU - Piantadosi, S.

PY - 1989

Y1 - 1989

N2 - Since 1980, adults with acurate myelocytic leukemia (AML) have been treated on two clinical studies using intensive timed sequential therapy. All patients ages 16 to 80, including those with secondary AML (SAML) and those with AML preceded by a hematologic disorder (AHD), were treated, regardless of medical complications at the time of diagnosis. The first study combined high doses of cytarabine (ara-C, AC) and daunorubicin (DRN, D) in sequence (Ac2-D-Ac) and resulted in a complete remission rate of 55%. A group of these patients selected by functional status was able to receive a second course of therapy in remission, which resulted in a disease-free survival (DFS) of >40% at 7 years. Because of toxicity in that study, 114 patients were entered on a second trial initiated 4 years ago, using a less aggressive first course, with amsacrine, to achieve a stable remission (Ac2-D-Amsa). The first treatment was followed by a more intensive second course (Ac6-D-Ac). With this two-step approach, a higher complete remission (CR) rate (76% for the de novo AML and 54% for SAML-AHD) was achieved, and more patients were able to receive the second course of therapy. At the current median follow-up of 26 months, the median duration of DFS and overall survival are 11 and 14 months for patients with de novo AML. Age ≤55 is the most significant prognostic factor for both prolonged DFS and overall survival, with median durations of 17 and 18 months, respectively, for these younger patients. Patients with SAML-AHD remain relatively refractory to treatment despite aggressive chemotherapy, with median durations of DFS and overall survival of 9 months and 5 months, respectively.

AB - Since 1980, adults with acurate myelocytic leukemia (AML) have been treated on two clinical studies using intensive timed sequential therapy. All patients ages 16 to 80, including those with secondary AML (SAML) and those with AML preceded by a hematologic disorder (AHD), were treated, regardless of medical complications at the time of diagnosis. The first study combined high doses of cytarabine (ara-C, AC) and daunorubicin (DRN, D) in sequence (Ac2-D-Ac) and resulted in a complete remission rate of 55%. A group of these patients selected by functional status was able to receive a second course of therapy in remission, which resulted in a disease-free survival (DFS) of >40% at 7 years. Because of toxicity in that study, 114 patients were entered on a second trial initiated 4 years ago, using a less aggressive first course, with amsacrine, to achieve a stable remission (Ac2-D-Amsa). The first treatment was followed by a more intensive second course (Ac6-D-Ac). With this two-step approach, a higher complete remission (CR) rate (76% for the de novo AML and 54% for SAML-AHD) was achieved, and more patients were able to receive the second course of therapy. At the current median follow-up of 26 months, the median duration of DFS and overall survival are 11 and 14 months for patients with de novo AML. Age ≤55 is the most significant prognostic factor for both prolonged DFS and overall survival, with median durations of 17 and 18 months, respectively, for these younger patients. Patients with SAML-AHD remain relatively refractory to treatment despite aggressive chemotherapy, with median durations of DFS and overall survival of 9 months and 5 months, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0024454404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024454404&partnerID=8YFLogxK

M3 - Article

C2 - 2676014

AN - SCOPUS:0024454404

VL - 74

SP - 1499

EP - 1506

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -